EUVIMEDEUVIMED entdecken
Crossref

Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019

Buonomo A Riccardo, Saccone Gabriele, Esposito Nunzia, Di Filippo Isabella, Pinchera Biagio, Foggia Maria, Zappulo Emanuela, Giaccone Agnese, Schiano M Nicola, Viceconte Giulio, Scotto Riccardo, Bifulco Giuseppe und 1 weitere

American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e612-e616

DOI: 10.1055/a-1925-2017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Buonomo A Riccardo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II Naples, Naples, Italy. Hauptthemen laut MEDLINE: Pregnancy Complications, Infectious, Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our objective was to evaluate the safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe coronavirus disease 2019 (COVID-19) requiring oxygen therapy. Study Design This was a prospective case series study aimed to evaluate the safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were severe acute respiratory syndrome coronavirus 2 infection documented with polymerase chain reaction, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, and able to provide informed consent. Vaccinated women and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as a single intravenous dose of 4,000/4,000 mg. Women were also treated with low molecular weight heparin, steroids, and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were the rate of adverse events during infusion or within 72 hours and the rate of abortion.

Results

Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to the intensive care unit. No abortion or fetal loss was recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries.

Conclusion

Casirivimab/imdevimab therapy may be considered as a therapy in unvaccinated pregnant women with severe COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy Complications, InfectiousAntibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentSARS-CoV-2HumansFemalePregnancyAdultProspective StudiesCOVID-19Antiviral AgentsHospitalizationDrug CombinationsOxygen Inhalation TherapyAntibodies, Neutralizing

Substanzen

Antibodies, Monoclonal, Humanizedcasirivimab and imdevimab drug combinationAntiviral AgentsDrug CombinationscasirivimabAntibodies, Neutralizing

Autor:innen und Institutionen

  • Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II Naples, Naples, Italy.
  • Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.

Zitieren

APA

Riccardo, B. A., Gabriele, S., Nunzia, E., Isabella, D. F., Biagio, P., Maria, F., Emanuela, Z., Agnese, G., Nicola, S. M., Giulio, V., Riccardo, S., Giuseppe, B., & Ivan, G. (2024). Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. American Journal of Perinatology, 41(S 01 S 01), e612-e616. https://doi.org/10.1055/a-1925-2017

Vancouver

Riccardo BA, Gabriele S, Nunzia E, Isabella DF, Biagio P, Maria F, et al. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. American Journal of Perinatology. 2024;41(S 01 S 01):e612-e616. doi:10.1055/a-1925-2017

BibTeX
@article{Riccardo2024,
  author = {Riccardo, Buonomo A and Gabriele, Saccone and Nunzia, Esposito and Isabella, Di Filippo and Biagio, Pinchera and Maria, Foggia and Emanuela, Zappulo and Agnese, Giaccone and Nicola, Schiano M and Giulio, Viceconte and Riccardo, Scotto and Giuseppe, Bifulco and Ivan, Gentile},
  title = {Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019},
  journal = {American Journal of Perinatology},
  year = {2024},
  volume = {41},
  number = {S 01 S 01},
  pages = {e612--e616},
  doi = {10.1055/a-1925-2017}
}
Kostenlos starten →